GRI Bio CEO, Marc Hertz, Participates in Virtual Investor “What This Means” Segment
GRI Bio (NASDAQ: GRI), a biotechnology company focused on developing Natural Killer T (NKT) cell modulators, announced CEO Marc Hertz's participation in a Virtual Investor "What This Means" segment. During the presentation, Dr. Hertz discussed the company's recently announced 6-week interim biomarker data from their ongoing Phase 2a study in Idiopathic Pulmonary Fibrosis (IPF).
GRI Bio (NASDAQ: GRI), un'azienda biotecnologica specializzata nello sviluppo di modulatori delle cellule Natural Killer T (NKT), ha annunciato la partecipazione del CEO Marc Hertz a una sessione virtuale per investitori intitolata "What This Means". Durante la presentazione, il dott. Hertz ha illustrato i dati preliminari sui biomarcatori a 6 settimane recentemente annunciati derivanti dal loro studio di Fase 2a in corso sulla Fibrosi Polmonare Idiopatica (IPF).
GRI Bio (NASDAQ: GRI), una empresa biotecnológica centrada en el desarrollo de moduladores de células Natural Killer T (NKT), anunció la participación del CEO Marc Hertz en un segmento virtual para inversores titulado "What This Means". Durante la presentación, el Dr. Hertz habló sobre los datos interinos de biomarcadores a 6 semanas recientemente anunciados de su estudio en curso de Fase 2a en Fibrosis Pulmonar Idiopática (IPF).
GRI Bio (NASDAQ: GRI)는 자연 살해 T세포(NKT) 조절제 개발에 주력하는 생명공학 회사로, CEO 마크 허츠가 가상 투자자 세션 "What This Means"에 참여했다고 발표했습니다. 발표 중 허츠 박사는 특발성 폐섬유증(IPF)을 대상으로 진행 중인 2a상 연구에서 최근 발표된 6주차 중간 바이오마커 데이터에 대해 설명했습니다.
GRI Bio (NASDAQ: GRI), une société de biotechnologie spécialisée dans le développement de modulateurs des cellules Natural Killer T (NKT), a annoncé la participation de son PDG Marc Hertz à une session virtuelle pour investisseurs intitulée « What This Means ». Lors de la présentation, le Dr Hertz a discuté des données intermédiaires sur les biomarqueurs à 6 semaines récemment annoncées issues de leur étude de phase 2a en cours sur la fibrose pulmonaire idiopathique (IPF).
GRI Bio (NASDAQ: GRI), ein Biotechnologieunternehmen, das sich auf die Entwicklung von Natural Killer T (NKT)-Zellmodulatoren spezialisiert hat, gab bekannt, dass CEO Marc Hertz an einem virtuellen Investoren-Segment "What This Means" teilnimmt. Während der Präsentation erläuterte Dr. Hertz die kürzlich bekannt gegebenen 6-Wochen-Zwischendaten zu Biomarkern aus der laufenden Phase-2a-Studie zur idiopathischen Lungenfibrose (IPF).
- None.
- None.
Access the “What This Means” segment here
LA JOLLA, CA, July 31, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it participated in a Virtual Investor “What This Means” segment.
For the segment, Marc Hertz, PhD, President, Chief Executive Officer and Director of GRI, discussed the Company’s recently announced 6-week interim biomarker data from its ongoing Phase 2a study in Idiopathic Pulmonary Fibrosis (“IPF”).
The “What This Means” segment can be accessed here.
About GRI Bio, Inc.
GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of Natural Killer T (“NKT”) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type I invariant NKT (“iNKT”) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 diverse NKT (“dNKT”) agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
GRI@jtcir.com
FAQ
What did GRI Bio CEO discuss in the Virtual Investor segment?
What is GRI Bio's main focus in drug development?
What clinical trial is GRI Bio currently conducting?
Who is the CEO of GRI Bio (NASDAQ: GRI)?
